Insulin-like growth factor 1 (IGF-1) is a 70-amino-acid single-chain polypeptide that serves as the primary downstream mediator of growth hormone (GH) action and plays central roles in cellular proliferation, differentiation, survival, and metabolism across virtually all mammalian tissues. IGF-1 LR3 (Long Arg3 IGF-1) is a recombinant analogue of human IGF-1 engineered for extended bioactivity in research applications, and its use in growth factor signalling studies has provided substantial mechanistic insights into IGF-1 receptor biology and anabolic pathway regulation.
IGF-1 LR3: Engineering and Pharmacological Properties
IGF-1 LR3 incorporates two key structural modifications relative to native IGF-1. First, a 13-amino-acid N-terminal extension is added to the native IGF-1 sequence. Second, the glutamic acid at position 3 is substituted with arginine. These modifications, while preserving IGF-1 receptor (IGF-1R) binding affinity, dramatically reduce IGF-1 LR3’s affinity for the six IGF binding proteins (IGFBP-1 through IGFBP-6) that normally sequester circulating IGF-1 and regulate its bioavailability in vivo.
In cell culture systems, native IGF-1 is rapidly sequestered by secreted IGFBPs in conditioned media, limiting its sustained receptor engagement. Research using IGF-1 LR3 has leveraged its reduced IGFBP affinity to maintain persistent IGF-1R activation in cell culture experiments, enabling investigators to study downstream signalling events with a more sustained and consistent growth factor stimulus than is achievable with native IGF-1. This property has made IGF-1 LR3 particularly valuable for studies requiring prolonged IGF-1R pathway activation without repeated supplementation of growth factor to the culture medium.
IGF-1 Receptor Signalling: PI3K/AKT and MAPK/ERK Pathways
Upon ligand binding, IGF-1R undergoes autophosphorylation at multiple tyrosine residues in its intracellular kinase domain, recruiting insulin receptor substrate (IRS) proteins and initiating divergent downstream signalling cascades. Research using IGF-1 LR3 in various cell systems has been instrumental in characterising the two primary IGF-1R signalling branches: the PI3K/AKT/mTOR pathway and the RAS/MAPK/ERK pathway.
The PI3K/AKT/mTOR pathway mediates IGF-1’s pro-survival and anabolic effects. AKT phosphorylation activates mTORC1, which drives ribosomal biogenesis, cap-dependent mRNA translation, and protein synthesis through phosphorylation of p70S6K1 and inhibition of 4E-BP1. Research in myocyte cultures and primary muscle cell systems has extensively documented IGF-1 LR3-stimulated mTORC1 activation and its downstream effects on muscle protein synthetic rate, measured using puromycin incorporation assays and stable isotope labelling approaches.
The MAPK/ERK pathway, activated in parallel through GRB2/SOS-mediated RAS activation, primarily mediates IGF-1’s mitogenic effects — stimulating cell cycle progression from G1 to S phase through ERK-dependent transcription of cyclin D1 and downregulation of cyclin-dependent kinase inhibitors. Research has used IGF-1 LR3 in proliferation assays (BrdU incorporation, Ki67 immunostaining, EdU labelling) across cancer cell lines, primary satellite cells, and other proliferating cell types to characterise the mitogenic signalling landscape of IGF-1R activation.
Muscle Biology Research and Satellite Cell Studies
Skeletal muscle biology research has been a particularly productive application area for IGF-1 LR3. Satellite cells — the myogenic progenitor cells responsible for adult muscle repair and regeneration — express high levels of IGF-1R and respond robustly to IGF-1 stimulation. Research using IGF-1 LR3 in primary satellite cell cultures has characterised the sequential signalling events governing satellite cell activation, proliferation, and differentiation into mature myotubes.
Studies have documented IGF-1 LR3-stimulated AKT-mediated phosphorylation and nuclear exclusion of FOXO transcription factors, which would otherwise drive muscle atrophy gene expression programs including the E3 ubiquitin ligases atrogin-1 and MuRF1. This regulation connects IGF-1 signalling to proteasomal protein degradation pathways, with implications for muscle hypertrophy and atrophy research. Animal model studies using recombinant IGF-1 variants have further extended these in vitro findings to characterise in vivo effects on muscle fibre cross-sectional area, fibre type composition, and neuromuscular junction morphology.
Wellchain.care supplies IGF-1 LR3 1mg for research use. Researchers studying the GH/IGF-1 axis may also be interested in HGH 10 IU for upstream GH receptor signalling research, and CJC-1295 + Ipamorelin 10mg for studying secretagogue-stimulated GH axis activation.
All compounds are supplied for research use only. Not for human consumption.
